Company’s 36-month beta value is 1.79.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PGEN is 161.93M, and currently, short sellers hold a 17.06% ratio of that floaft. The average trading volume of PGEN on June 18, 2025 was 1.55M shares.
PGEN) stock’s latest price update
Precigen Inc (NASDAQ: PGEN) has experienced a decline in its stock price by -7.79 compared to its previous closing price of 1.54. However, the company has seen a fall of -7.79% in its stock price over the last five trading days. prnewswire.com reported 2025-05-14 that PRGN-2012 has the potential to be the first- and best-in-class treatment for RRP Company’s BLA for PRGN-2012 for the treatment of adults with RRP is under priority review by the FDA with a PDUFA target action date set for August 27, 2025 RRP is a rare, debilitating chronic disease with approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US Company continues to rapidly advance commercial and manufacturing readiness campaign in anticipation of 2025 commercial launch Company and Recurrent Respiratory Papillomatosis Foundation to host the 2025 International RRP Awareness Day on June 11 Cash, cash equivalents, and investments of $81.0 million as of March 31, 2025 are anticipated to fund operations into 2026, beyond the potential 2025 commercial launch of PRGN-2012 GERMANTOWN, Md., May 14, 2025 /PRNewswire/ — Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced first quarter 2025 financial results and business updates.
PGEN’s Market Performance
PGEN’s stock has fallen by -7.79% in the past week, with a monthly drop of -2.07% and a quarterly drop of -14.97%. The volatility ratio for the week is 4.54% while the volatility levels for the last 30 days are 4.40% for Precigen Inc The simple moving average for the last 20 days is 0.11% for PGEN’s stock, with a simple moving average of 14.80% for the last 200 days.
Analysts’ Opinion of PGEN
Cantor Fitzgerald gave a rating of “Overweight” to PGEN, setting the target price at $7 in the report published on November 18th of the previous year.
PGEN Trading at 0.02% from the 50-Day Moving Average
After a stumble in the market that brought PGEN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.56% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PGEN starting from Perez Jeffrey Thomas, who purchase 58,823 shares at the price of $0.85 back on Aug 09 ’24. After this action, Perez Jeffrey Thomas now owns 743,097 shares of Precigen Inc, valued at $50,000 using the latest closing price.
KIRK RANDAL J, the Director of Precigen Inc, purchase 23,529,411 shares at $0.85 during a trade that took place back on Aug 09 ’24, which means that KIRK RANDAL J is holding 64,547,214 shares at $19,999,999 based on the most recent closing price.
Stock Fundamentals for PGEN
Current profitability levels for the company are sitting at:
- -31.71 for the present operating margin
- -0.02 for the gross margin
The net margin for Precigen Inc stands at -37.29. The total capital return value is set at -1.27. Equity return is now at value -278.55, with -118.84 for asset returns.
Based on Precigen Inc (PGEN), the company’s capital structure generated -0.63 points at debt to capital in total, while cash flow to debt ratio is standing at -13.0. The debt to equity ratio resting at -0.39. The interest coverage ratio of the stock is -26643.0.
Currently, EBITDA for the company is -123.5 million with net debt to EBITDA at 0.0. When we switch over and look at the enterprise to sales, we see a ratio of 99.62. The receivables turnover for the company is 3.95for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.53.
Conclusion
In a nutshell, Precigen Inc (PGEN) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
